Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.900
+0.020 (1.06%)
At close: Apr 28, 2026, 4:00 PM EDT
1.940
+0.040 (2.11%)
After-hours: Apr 28, 2026, 6:03 PM EDT
Acrivon Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Acrivon Therapeutics stock have an average target of 11.67, with a low estimate of 8.00 and a high estimate of 19. The average target predicts an increase of 514.21% from the current stock price of 1.90.
Analyst Consensus: Buy
* Price targets were last updated on Jan 9, 2026.
Analyst Ratings
The average analyst rating for Acrivon Therapeutics stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 4 | 4 | 4 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 6 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $6 → $8 | Buy | Maintains | $6 → $8 | +321.05% | Jan 9, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +900.00% | Nov 25, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $9 → $8 | Buy | Maintains | $9 → $8 | +321.05% | Aug 14, 2025 |
| Jones Trading | Jones Trading | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 16, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $10 → $9 | Buy | Maintains | $10 → $9 | +373.68% | May 15, 2025 |
Financial Forecast
Revenue This Year
1.53M
Revenue Next Year
10.22M
from 1.53M
Increased by 568.17%
EPS This Year
-2.22
from -2.02
EPS Next Year
-1.99
from -2.22
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 11.0M | 45.1M | ||||||
| Avg | 1.5M | 10.2M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 2,848.8% | ||||||
| Avg | - | 568.2% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.79 | -1.33 | ||||||
| Avg | -2.22 | -1.99 | ||||||
| Low | -2.68 | -2.46 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.